HERO-MOTOCORP
1.7.2024 16:24:30 CEST | Business Wire | Press release
Hero MotoCorp, the world's largest motorcycle and scooter manufacturer, is paying tribute to its visionary Founder Chairman, Dr. Brijmohan Lall Munjal, with the collector's edition motorcycle, 'The Centennial.'
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240701062737/en/
The Centennial (Photo: Business Wire)
"Dr. Brijmohan Lall Munjal, my father and Founder Chairman of Hero MotoCorp, inspired billions worldwide. His vision transformed the landscape of the Indian automotive industry, and the Indian industry, leaving behind a legacy of ingenuity, innovation, courage and integrity. For him, business transcended profit - it was about people, both the individual and the community.
"As we celebrate the completion of one year of his centennial anniversary, I am overwhelmed and proud to introduce ‘The Centennial’ - a marvel of engineering crafted in honour of his legacy. ‘The Centennial’ is not merely a landmark motorcycle but a memoir, written in steel and carbon fibre. This magnificent machine's design, engineering and technology all reflect the indelible mark of our inspiring Founder.
"His inclusive vision embraced everyone in the Hero community – our customers, employees, dealers, partners, suppliers, and other stakeholders. Over these 100 days, we celebrate the man who started it all. I invite everyone to join us in honouring Dr. Brijmohan Lall Munjal on his 101st birth anniversary."
Dr. Pawan Munjal
Executive Chairman
Hero MotoCorp
'The Centennial' was conceptualised, designed and developed by the global experts at the Hero Centre for Innovation and Technology (CIT) in India and the Hero Tech Centre in Germany (TCG). This masterpiece reflects the company's commitment to innovation and excellence. With only 100 meticulously handcrafted units, it embodies premium performance and craftsmanship.
In honour of Dr. Brijmohan Lall Munjal's 101st birth anniversary, the company will auction these bikes to its employees, associates, business partners, and stakeholders. The proceeds from the contributions will be utilised for the society's greater good, reflecting the Founder's enduring value of giving back to the community.
Deliveries of ‘The Centennial’ will begin in September 2024.
Additionally, driven by its commitment to inclusivity and sustainability, the company is celebrating 100 days of customer and employee engagements across its facilities and dealer network, including its Global markets. During this period, customers who buy any Hero motorcycle or scooter will have the unique opportunity to receive 100% cashback on their purchase. This offer is available for a limited number of 100 vehicles. Further details are available on the company website and social media platforms.
Hero MotoCorp will also be inviting its customers to partake in the ‘My Hero, My Story’ campaign, where they can share anecdotes showcasing their unique bond and journey with the brand. A distinguished panel of experts from diverse backgrounds will carefully evaluate the submissions, and the top entries will be rewarded with the coveted ‘The Centennial.’
The Centennial
‘The Centennial’ stands out with its exceptional craftsmanship, carbon fibre and milled aluminium usage, and meticulous engineering.
Its distinctive elements include a lightweight aluminium swingarm for an enhanced riding experience and newly designed carbon fibre body panels for sleek aesthetics and structural rigidity. ‘The Centennial’ features are specially developed, machined, and anodised, including handlebars, handlebar mounts, triple clamps, and rear-set foot pegs.
Delivering impressive performance and agility, the bike is equipped with a gas-charged, fully adjustable mono-shock from Wilbers and a 43-mm upside-down front suspension with damping adjustment.
A distinct, deep exhaust note emanates from the top-of-the-line carbon fibre and titanium exhaust system by Akrapovic, which is specially tuned for peak performance and integrates seamlessly with the bike.
The solo seat with a carbon fibre seat cowl and milled aluminium special edition numbered badging on the side covers add to the bike's uniqueness and exclusivity. Attention to detail is evident in the diamond-cut alloy wheels and the engine and frame's paint scheme, which enhance the motorcycle's visual appeal.
With a low kerb weight of 158 kg, ‘The Centennial’ is exceptionally light, offering superior throttle response and improved handling and braking performance.
For more information, please visit - https://www.heromotocorp.com/en-in/the-centennial.html
For more information on Hero MotoCorp:
https://www.heromotocorp.com/en-in/
https://www.facebook.com/HeroMotoCorpIndia
https://twitter.com/HeroMotoCorp
https://www.instagram.com/heromotocorp/
https://www.youtube.com/c/HeroMotoCorp
https://www.linkedin.com/company/heromotocorp/mycompany/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240701062737/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
